An interventional study of Transcranial temporal interference stimulation and Transcranial temporal interference stimulation in Parkinson Disease, sponsored by Ruijin Hospital. Completed at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Parkinson Disease by Ruijin Hospital — 8 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · Ruijin Hospital.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 with no phase, and was the 14th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →8 of the 20 studies in Parkinson Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 50–85
Ruijin Hospital · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 40–65
Ruijin Hospital · Sites in China
Ruijin Hospital · Sites in China
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 29 across the 18 interventional studies, 360 across the 2 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
2 of the studies in Parkinson Disease by Ruijin Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07353463Ruijin HospitalShanghai Clinical Cohort - Parkinson's Disease (Reserve) | 2026-12-31 |
| NCT07774312Ruijin HospitalSTN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the therapeutic efficacy of tTIS in patients with Parkinson's disease and to evaluate the immediate effects and conduct intrapatient comparisons of individualized 130 Hz Subthalamic Nucleus-transcranial Temporal Interference Stimulation (STN-tTIS) and Globus Pallidus Internus-transcranial Temporal Interference Stimulation (GPi-tTIS) on motor symptoms in patients with early to mid-stage Parkinson's Disease (PD) during "off" medication states.
The main questions this study aims to answer are:
This clinical trial aims to verify the efficacy of tTIS in patients with Parkinson's disease and to explore which targets are better for improving PD motor symptoms.Patients were randomly assigned to receive Stimulation Type A, B, or C. Type A received STN-tTIS therapy; Type B received GPi-tTIS therapy; Type C received sham stimulation targeting the subthalamic nucleus.
Each session lasted 20 minutes, and patients were in the off-medication state for all treatments.The order of stimulation types was randomized, with at least 7 days of washout between sessions to avoid carryover effects. MDS-UPDRS-III evaluations were assessed before and after each treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this group receive 20 minutes of individualized 130 Hz STN-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ before and after treatment.
Device: Transcranial temporal interference stimulation
Patients in this group receive 20 minutes of individualized 130 Hz GPi-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ both before and after treatment.
Device: Transcranial temporal interference stimulation
Patients in this group receive sham stimulation targeting the subthalamic nucleus in the more affected hemisphere during the medication "off" state. Sham uses each participant's own STN-tTIS montage, with both channels delivering 2000 Hz so that the stimulation beat frequency is 0 Hz and no interference envelope is produced. Current is ramped up over 30 seconds and back to 0 mA over the next 30 seconds, with no stimulation for the remainder of the session. Each session lasts 20 minutes, and the MDS-UPDRS-III is assessed both before and after treatment.
Device: Transcranial temporal interference stimulation
To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling.
To design the individualized GPi-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data is used to determine the GPi-tTIS montage and stimulation settings via computational modeling.
To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling. Sham stimulation replicated this montage without producing an interference envelope.
MDS-UPDRS-Ⅲ scores
The score range for MDS-UPDRS-III is from 0 to 132. The minimum value is 0, indicating no motor impairment, and the maximum value is 132, indicating the most severe motor impairment. Higher scores on the MDS-UPDRS-III indicate worse outcomes, as they reflect greater severity of motor symptoms.
Time frame: pre-intervention, immediately after the intervention
MDS-UPDRS-Ⅲ sub-scores
The MDS-UPDRS-III assesses motor symptoms in Parkinson's disease through sub-scores: Tremor Sub-score: Items 3.15-3.18; range 0-16. Higher scores indicate more severe tremors. Rigidity Sub-score: Item 3.3 (neck and four limbs); range 0-20. Higher scores reflect greater rigidity. Bradykinesia Sub-score: Items 3.2, 3.4-3.8, and 3.14; range 0-28. Higher scores indicate more severe slowness of movement. Axial Sub-score: Items 3.1 and 3.9-3.13; range 0-24. Higher scores suggest more significant axial impairments.
Time frame: pre-intervention, immediately after the intervention
Number of participants with adverse events
Adverse events were assessed by volunteered report and categorized by preferred term and severity (mild, moderate, severe). The number of participants experiencing at least one adverse event was summarized for each stimulation condition in the safety population (all participants exposed to any condition). Serious adverse events were summarized separately.
Time frame: During each 20-minute intervention session and through the post-intervention assessment on the same day
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Apr 2026, 7 months.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 7 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Apr 2025 → Aug 2025, primary completion Nov 2026 → Apr 2026 and completion Nov 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.